Advancements in rheumatoid arthritis therapy: a journey from conventional therapy to precision medicine via nanoparticles targeting immune cells
Nanoscale,
Год журнала:
2024,
Номер
16(32), С. 14975 - 14993
Опубликована: Янв. 1, 2024
Rheumatoid
arthritis
(RA)
is
a
progressive
autoimmune
disease
that
mainly
affects
the
inner
lining
of
synovial
joints
and
leads
to
chronic
inflammation.
While
RA
not
known
as
lethal,
recent
research
indicates
it
may
be
silent
killer
because
its
strong
association
with
an
increased
risk
lung
heart
diseases.
Patients
develop
these
systemic
consequences
due
regular
uptake
heavy
drugs
such
disease-modifying
antirheumatic
medications
(DMARDs),
glucocorticoids
(GCs),
nonsteroidal
anti-inflammatory
medicines
(NSAIDs),
Язык: Английский
Bridging the gap in rheumatoid arthritis treatment with hyaluronic acid-based drug delivery approaches
International Journal of Biological Macromolecules,
Год журнала:
2024,
Номер
271, С. 132586 - 132586
Опубликована: Май 23, 2024
Язык: Английский
Xuetongsu Ameliorates Synovial Inflammatory Hyperplasia in Rheumatoid Arthritis by Inhibiting JAK2/STAT3 and NF-κB Signaling Pathways
Journal of Ethnopharmacology,
Год журнала:
2024,
Номер
337, С. 118786 - 118786
Опубликована: Сен. 6, 2024
Язык: Английский
MCP-1 and IL-4 encapsulated hydrogel particles with macrophages enrichment and polarization capabilities for systemic lupus erythematosus treatment
Nano Research,
Год журнала:
2024,
Номер
17(9), С. 8316 - 8324
Опубликована: Июнь 26, 2024
Язык: Английский
Application of Microsponge Drug Platform to Enhance Methotrexate Administration in Rheumatoid Arthritis Therapy
Pharmaceutics,
Год журнала:
2024,
Номер
16(12), С. 1593 - 1593
Опубликована: Дек. 13, 2024
Background/Objectives:
This
study
aimed
to
develop
a
novel
nanotechnological
slow-release
drug
delivery
platform
based
on
hyaluronic
acid
Microsponge
(MSP)
for
the
subcutaneous
administration
of
methotrexate
(MTX)
in
treatment
rheumatoid
arthritis
(RA).
RA
is
chronic
autoimmune
disease
characterized
by
joint
inflammation
and
damage,
while
MTX
common
disease-modifying
antirheumatic
(DMARD),
conventional
use
which
limited
adverse
effects
lack
release
control.
Methods:
MSP
were
synthesized
as
freeze-dried
powder
increase
their
stability
allow
facile
reconstitution
prior
precise
dosing.
Results:
A
highly
stable
rounded-shaped
micrometric
MSP,
an
open
porosity
inner
structure,
achieved
both
high
loading
efficiency
slow
after
injection.
Our
assays
indeed
demonstrated
characteristic
profile
consisting
very
burst
first
few
hours,
followed
sustained
over
month.
By
means
preclinical
rat
model
RA,
MTX-loaded
proved
nearly
double
therapeutic
efficacy
compared
sole
MTX,
according
steep
reduction
arthritic
score
control
groups.
The
was
replicated
twice
confirm
this
improvement
performance
safety
MSP.
Conclusions:
suggests
that
holds
significant
potential
clinical
improving
therapy
enabling
thereby
enhancing
outcomes
minimizing
side
associated
with
burst-release
administration.
Язык: Английский